A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43% Market Closed
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note

Net Margin
AFT Pharmaceuticals Ltd

5.9%
Current
9%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.9%
=
Net Income
11.6m
/
Revenue
198.5m

Net Margin Across Competitors

Country NZ
Market Cap 297.8m NZD
Net Margin
6%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 750.9B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.8T DKK
Net Margin
35%
Country US
Market Cap 346.5B USD
Net Margin
17%
Country US
Market Cap 250.3B USD
Net Margin
19%
Country CH
Market Cap 199.5B CHF
Net Margin
20%
Country UK
Market Cap 161.2B GBP
Net Margin
13%
Country CH
Market Cap 171.3B CHF
Net Margin
35%
Country US
Market Cap 149.9B USD
Net Margin
7%
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.9%
=
Net Income
11.6m
/
Revenue
198.5m
What is the Net Margin of AFT Pharmaceuticals Ltd?

Based on AFT Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of 5.9%.